From: Impact of acute renal failure on plasmatic levels of cleaved endocan
Variables | Absent | Present | Spearman ρ (95% CI) | p |
---|---|---|---|---|
Age (years) | 0.18 (− 0.03–0.37) | 0.08 | ||
Chronic comorbidities | ||||
COPD | 0.33 [0.21–0.42] | 0.23 [0.18–0.51] | 0.53 | |
Smoker | 0.33 [0.21–0.45] | 0.23 [0.18–0.35] | 0.15 | |
Cardiomyopathy | 0.3 [0.2–0.42] | 0.33 [0.2–0.45] | 0.61 | |
Chronic kidney failure | 0.31 [0.21–0.44] | 0.25 [0.05–0.56] | 0.7 | |
Cirrhosis | 0.31 [0.2–0.45] | 0.3 [0.21–0.37] | 0.63 | |
Sepsis severity on enrolment | ||||
Severe sepsis | 0.29 [0.2–0.41] | |||
Septic shock | 0.31 [0.2–0.45] | 0.74 | ||
Site of infection on enrolment | ||||
Soft tissues | 0.3 [0.2–0.39] | |||
Respiratory | 0.33 [0.21–0.45] | |||
Urinary | 0.31 [0.22–0.53] | 0.82 | ||
Digestive | 0.31 [0.24–0.38] | |||
Other | 0.21 [0.07–0.49] | |||
Biomarkers on enrolment | ||||
CRP (mg/L) | 0 (−0.21–0.2) | 0.96 | ||
PCT (ng/mL) | 0.06 (− 0.15–0.26) | 0.58 | ||
Prognostic scores on enrolment | ||||
SAPS 2 | 0.36 (0.17–0.53) | < 10−3 | ||
SOFA | 0.21 (0–0.39) | 0.04 | ||
LIPS | 0.12 (−0.08–0.32) | 0.22 | ||
Organ SOFA > 2 on enrolment | ||||
Pulmonary | 0.3 [0.2–0.37] | 0.35 [0.24–0.48] | 0.19 | |
Renal | 0.28 [0.19–0.36] | 0.38 [0.29–0.61] | < 10− 3 | |
Hepatic | 0.32 [0.21–0.42] | 0.26 [0.14–0.53] | 0.75 | |
Circulatory | 0.23 [0–0.39] | 0.33 [0.23–0.45] | 0.12 | |
Neurological | 0.3 [0.2–0.38] | 0.33 [0.24–0.48] | 0.19 | |
Hematological | 0.31 [0.2–0.4] | 0.27 [0.12–0.54] | 0.99 | |
Mortality | ||||
Day 28 | 0.3 [0.19–0.38] | 0.33 [0.23–0.48] | 0.4 | |
ICU discharge | 0.3 [0.2–0.37] | 0.33 [0.23–0.54] | 0.24 | |
ICU length of stay (days) | 0.16 (−0.04–0.35) | 0.11 | ||
Mechanical ventilation on enrolment | 0.3 [0.19–0.37] | 0.31 [0.23–0.47] | 0.33 |